RaySearch Laboratories AB Reports Record Q1 Performance

Stockholm, May 9, 2025 — RaySearch Laboratories AB, a leading medical technology company specializing in cancer treatment solutions, has reported a record-breaking first quarter for 2025. The company, listed on the Swedish Stock Exchange, announced exceptional financial results, surpassing expectations and setting the stage for continued growth.

Financial Highlights

  • Order Intake: RaySearch reported an order intake of SEK 409.6 million, a significant increase from SEK 238.5 million in the same period last year.
  • Net Sales: The company achieved net sales of SEK 331.7 million, up from SEK 257.2 million.
  • Operating Profit: Operating profit rose to SEK 74.8 million, compared to SEK 45.8 million.
  • Profit After Tax: Profit after tax reached SEK 56.8 million, up from SEK 36.7 million.
  • Earnings Per Share: Earnings per share before and after dilution showed a substantial increase.

Market Reaction

The financial community has responded positively to RaySearch’s performance. The company’s stock surged by over 20% following the release of the interim report, reflecting investor confidence in its growth trajectory. The broader Stockholm Stock Exchange saw modest gains, with the OMXSPI index up by 0.2% and the OMXS30 index by 0.1%.

Company Overview

RaySearch Laboratories AB, headquartered in Stockholm, Sweden, is renowned for its innovative software solutions in radiation therapy. Its flagship product, RayStation, supports a wide range of treatment activities, including automated planning, adaptive therapy, and machine learning applications. The company also offers RayPlan and RayCare, enhancing treatment planning and oncology information systems, respectively.

Strategic Alliances and Future Outlook

Established in 2000, RaySearch has formed strategic alliances to advance adaptive radiation therapy globally. The company’s strong Q1 performance is seen as a foundation for setting more records in the future, as noted by Redeye.se. With a market capitalization of SEK 7.46 billion and a price-to-earnings ratio of 43.93, RaySearch continues to be a key player in the health care technology sector.

Conclusion

RaySearch Laboratories AB’s record Q1 results underscore its leadership in medical technology and its commitment to advancing cancer treatment. The company’s robust financial performance and strategic initiatives position it well for sustained growth in the coming years.